| New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) EA Eisenhauer, P Therasse, J Bogaerts, LH Schwartz, D Sargent, R Ford, ... European journal of cancer 45 (2), 228-247, 2009 | 27961 | 2009 |
| New guidelines to evaluate the response to treatment in solid tumors P Therasse, SG Arbuck, EA Eisenhauer, J Wanders, RS Kaplan, ... Journal of the national cancer institute 92 (3), 205-216, 2000 | 18862 | 2000 |
| Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study HU Ahmed, AES Bosaily, LC Brown, R Gabe, R Kaplan, MK Parmar, ... The Lancet 389 (10071), 815-822, 2017 | 2996 | 2017 |
| Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial TS Maughan, RA Adams, CG Smith, AM Meade, MT Seymour, RH Wilson, ... The Lancet 377 (9783), 2103-2114, 2011 | 1268 | 2011 |
| Participation of patients 65 years of age or older in cancer clinical trials JH Lewis, ML Kilgore, DP Goldman, EL Trimble, R Kaplan, MJ Montello, ... Journal of clinical oncology 21 (7), 1383-1389, 2003 | 1174 | 2003 |
| Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group GJ Bubley, M Carducci, W Dahut, N Dawson, D Daliani, M Eisenberger, ... Journal of Clinical Oncology 17 (11), 3461-3467, 1999 | 1141 | 1999 |
| Cancer surveillance series: interpreting trends in prostate cancer—part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates BF Hankey, EJ Feuer, LX Clegg, RB Hayes, JM Legler, PC Prorok, ... Journal of the National Cancer Institute 91 (12), 1017-1024, 1999 | 894 | 1999 |
| Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial AM Oza, AD Cook, J Pfisterer, A Embleton, JA Ledermann, ... The Lancet Oncology 16 (8), 928-936, 2015 | 884 | 2015 |
| Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies S Venderbosch, ID Nagtegaal, TS Maughan, CG Smith, JP Cheadle, ... Clinical Cancer Research 20 (20), 5322-5330, 2014 | 734 | 2014 |
| Brain and other central nervous system cancers: recent trends in incidence and mortality JM Legler, LAG Ries, MA Smith, JL Warren, EF Heineman, RS Kaplan, ... Journal of the National Cancer Institute 91 (16), 1382-1390, 1999 | 674* | 1999 |
| Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas HA Fine, WD Figg, K Jaeckle, PY Wen, AP Kyritsis, JS Loeffler, VA Levin, ... Journal of Clinical Oncology 18 (4), 708-708, 2000 | 588 | 2000 |
| How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials WB Sateren, EL Trimble, J Abrams, O Brawley, N Breen, L Ford, ... Journal of clinical oncology 20 (8), 2109-2117, 2002 | 577 | 2002 |
| A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant … EA Chiocca, KM Abbed, S Tatter, DN Louis, FH Hochberg, F Barker, ... Molecular Therapy 10 (5), 958-966, 2004 | 522 | 2004 |
| Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08 PY Wen, WKA Yung, KR Lamborn, PL Dahia, Y Wang, B Peng, LE Abrey, ... Clinical Cancer Research 12 (16), 4899-4907, 2006 | 502 | 2006 |
| Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results FF Lang, JM Bruner, GN Fuller, K Aldape, MD Prados, S Chang, ... Journal of Clinical Oncology 21 (13), 2508-2518, 2003 | 482 | 2003 |
| Prognostic factors in prostate cancer: College of American Pathologists consensus statement 1999 DG Bostwick, DJ Grignon, MEH Hammond, MB Amin, M Cohen, ... Archives of pathology & laboratory medicine 124 (7), 995-1000, 2000 | 461 | 2000 |
| The continuing increase in the incidence of primary central nervous system non‐Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis JE Olson, CA Janney, RD Rao, JR Cerhan, PJ Kurtin, D Schiff, RS Kaplan, ... Cancer 95 (7), 1504-1510, 2002 | 437 | 2002 |
| Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2 … P Cahn, JS Madero, JR Arribas, A Antinori, R Ortiz, AE Clarke, CC Hung, ... The Lancet 393 (10167), 143-155, 2019 | 398 | 2019 |
| Clinical trial designs for cytostatic agents: are new approaches needed? EL Korn, SG Arbuck, JM Pluda, R Simon, RS Kaplan, MC Christian Journal of Clinical Oncology 19 (1), 265-272, 2001 | 383 | 2001 |
| Prognostic indicators of colon tumors. The gastrointestinal tumor study group experience SM Steinberg, JS Barkin, RS Kaplan, DM Stablein Cancer 57 (9), 1866-1870, 1986 | 380 | 1986 |
